Physician profile

Christopher Alan Snyder

Dermatology · Charlotte, NC

NPI 1912973801

$24,245.39

in general payments reported to CMS, 2019-2025

43 companies · $5,590 in 2025

The $5,590 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$13,329.77
Education$375.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $3,367.92 2019-2025 Skyrizi, Rinvoq, Humira
Janssen Biotech, INC. $2,591.76 2019-2025 Tremfya
Sun Pharmaceutical Industries INC. $1,822.92 2019-2025 Ilumya, Winlevi
Genzyme Corporation $1,546.45 2019-2025
Ucb, INC. $1,477.03 2019-2025 Bimzelx, Cimzia
Lilly USA, LLC $1,465.82 2019-2025 Taltz, Ebglyss, Olumiant
Leo Pharma INC. $1,417.74 2019-2025 Adbry, Anzupgo
Regeneron Healthcare Solutions, INC. $1,214.32 2019-2025 Dupixent, Libtayo
Pfizer INC. $1,177.49 2019-2025
Galderma Laboratories, L.P. $954.29 2019-2025 Nemluvio, Aklief, Epsolay
Amgen INC. $943.44 2019-2025 Otezla, Otezla
Incyte Corporation $743.34 2021-2025 Opzelura
Novartis Pharmaceuticals Corporation $734.70 2019-2025
E.R. Squibb & Sons, L.L.C. $694.35 2022-2025 Sotyktu
Biofrontera INC. $560.71 2019-2024 Xepi, Bf-Rhodoled, Ameluz
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Dermavant Sciences, INC. $560.60 2023-2024 Vtama
Hill Dermaceuticals, INC. $454.54 2024 Tolak
Almirall LLC $423.58 2019-2024 Klisyri
Arcutis Biotherapeutics, INC. $342.02 2023-2025 Zoryve
Mayne Pharma Commercial LLC $218.41 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $180.36 2022-2025 Spevigo, Cyltezo
Organon LLC $179.45 2025 Vtama
Medimetriks Pharmaceuticals, INC. $170.11 2023-2024 Clindacin Etz, Neo-Synalar, Clodan
Helsinn Therapeutics (U.S.), INC. $156.18 2021-2023 Valchlor
Janssen Scientific Affairs, LLC $123.75 2019
Journey Medical Corporation $111.07 2019-2025
Dermira, INC. $88.98 2019-2021
Ortho Dermatologics, A Division of Bausch Health US, LLC $85.19 2020-2025 Cabtreo, Jublia
Ani Pharmaceuticals, INC. $64.19 2023 Veregen
Strata Skin Sciences, INC. $61.74 2022-2025 Xtrac
Sandoz INC. $54.55 2019
Epi Health, LLC $43.83 2019-2022
Organogenesis INC. $38.04 2024-2025 Puraply Am, Puraply Wound Matrix
Botanix Sb INC $28.70 2025 Sofdra
Fresenius Kabi USA, LLC $26.66 2024 Idacio
Convatec INC. $19.66 2024
Sebela Pharmaceuticals INC. $16.77 2021
Vyne Pharmaceuticals INC. $16.58 2021
Mission Pharmacal Company $15.03 2022
Nabriva Therapeutics, Plc $14.57 2021
Tactile Systems Technology INC $14.07 2021
Paratek Pharmaceuticals, INC. $12.94 2022
Dusa Pharmaceuticals, INC. $11.54 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher Alan Snyder

$24,245.39

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $5,590 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/267802/christopher-alan-snyder

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.